B+
Bull case
0%
Probability
Target price
$82.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
CRSP
CRISPR TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$59.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+82.1
Score
AI commentary
Post-earnings coverage is mildly constructive because of Casgevy growth and multiple second-half milestones, but the packet lacks robust analyst-revision data and social coverage. One Form 4 reported a chief medical officer open-market sale of 3,786 shares, which is not evidence of operating performance. [#SEC-FORM4-2026-06-01]
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-03eventQ2 results and Casgevy expansionMedium impact
The August 3 8-K reported $76 million of Q2 Casgevy revenue, up 78% quarter over quarter and 151% year over year, alongside FDA approval for patients aged two and older. Secondary earnings coverage characterized Q2 EPS and revenue as ahead of consensus. [#SEC-8K-2026-08-03] [#PR-EARNINGS-2026-08-04]
2026-08-28eventCTX310 durability data at ESC CongressHigh impact
A late-breaking CTX310 durability abstract is scheduled for presentation at the European Society of Cardiology Congress, with a Phase 1a update expected; the company also expects a Phase 1b update in the second half of 2026. [#SEC-8K-2026-08-03]
2027-08-13catalystSecond-half clinical pipeline executionHigh impact
CRSP has initiated Phase 1 studies for CTX340 in refractory hypertension and CTX460 in alpha-1 antitrypsin deficiency, while zugo-cel autoimmune studies continue. The value impact remains dependent on enrollment, safety, and early efficacy data. [#SEC-8K-2026-08-03]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology